Intuitive Surgical, Inc. $ISRG Stock Sold by Eurizon Capital SGR S.p.A.

Eurizon Capital SGR S.p.A. cut its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 6.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 237,653 shares of the medical equipment provider’s stock after selling 16,401 shares during the quarter. Eurizon Capital SGR S.p.A. owned 0.07% of Intuitive Surgical worth $96,883,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Bank of America Corp DE boosted its position in Intuitive Surgical by 3.3% during the 1st quarter. Bank of America Corp DE now owns 3,616,973 shares of the medical equipment provider’s stock worth $1,667,388,000 after acquiring an additional 116,292 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Intuitive Surgical in the second quarter valued at approximately $1,335,753,000. Amundi raised its holdings in shares of Intuitive Surgical by 8.6% in the first quarter. Amundi now owns 2,428,356 shares of the medical equipment provider’s stock valued at $1,119,448,000 after purchasing an additional 193,096 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in shares of Intuitive Surgical by 95.3% in the first quarter. Arrowstreet Capital Limited Partnership now owns 2,105,544 shares of the medical equipment provider’s stock valued at $970,635,000 after purchasing an additional 1,027,475 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. lifted its position in shares of Intuitive Surgical by 10.8% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,893,485 shares of the medical equipment provider’s stock worth $769,948,000 after purchasing an additional 184,044 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Stock Down 2.1%

NASDAQ:ISRG opened at $439.89 on Friday. The firm has a market capitalization of $152.48 billion, a price-to-earnings ratio of 53.19, a price-to-earnings-growth ratio of 3.10 and a beta of 1.45. Intuitive Surgical, Inc. has a twelve month low of $328.57 and a twelve month high of $603.88. The stock’s 50 day moving average price is $416.12 and its two-hundred day moving average price is $430.38.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.65 by $0.35. The company had revenue of $3.05 billion for the quarter, compared to analysts’ expectations of $2.91 billion. Intuitive Surgical had a return on equity of 18.17% and a net margin of 25.54%. The business’s revenue was up 21.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.40 EPS. As a group, analysts anticipate that Intuitive Surgical, Inc. will post 9.37 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on ISRG shares. Oppenheimer restated an “outperform” rating and set a $500.00 target price on shares of Intuitive Surgical in a report on Wednesday, October 21st. TD Cowen reaffirmed a “buy” rating and issued a $485.00 target price on shares of Intuitive Surgical in a research report on Monday, October 19th. Robert W. Baird lifted their price target on shares of Intuitive Surgical from $513.00 to $550.00 and gave the company an “outperform” rating in a research note on Wednesday, October 21st. Weiss Ratings reissued a “hold (c)” rating on shares of Intuitive Surgical in a research report on Friday, August 14th. Finally, Sanford C. Bernstein reissued an “outperform” rating on shares of Intuitive Surgical in a research report on Wednesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $493.54.

Insider Buying and Selling at Intuitive Surgical

In related news, Director Gary Guthart sold 20,095 shares of the business’s stock in a transaction on Friday, October 23rd. The shares were sold at an average price of $451.61, for a total transaction of $9,075,102.95. Following the transaction, the director directly owned 1,204,530 shares in the company, valued at approximately $543,977,793.30. The trade was a 1.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Craig Barratt sold 1,150 shares of the company’s stock in a transaction on Friday, October 23rd. The stock was sold at an average price of $443.80, for a total transaction of $510,370.00. Following the sale, the director directly owned 1,150 shares in the company, valued at $510,370. This trade represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 39,456 shares of company stock valued at $17,769,124 in the last 90 days. Company insiders own 0.60% of the company’s stock.

Intuitive Surgical Profile

Intuitive Surgical develops, manufactures and markets robotic-assisted systems for minimally invasive procedures. Its products include da Vinci surgical systems, which allow surgeons to control instruments and a high-definition vision system from a console, as well as the Ion endoluminal system, designed to assist with minimally invasive lung biopsies. The company also provides instruments, accessories, training and support services for its systems. Its technology is used in a range of surgical specialties, including urology, general surgery and gynecology.